Vir Biotechnology's hepatitis delta therapy meets primary endpoint in Phase 3 trial

• Vir Biotechnology’s elebsiran-tobevibart combination met primary and key secondary endpoints in the Phase 3 ECLIPSE 1 trial for chronic hepatitis delta.
• The regimen suppressed virus and normalized liver enzymes, with a favorable safety profile and no treatment interruptions or discontinuations.
• ECLIPSE 1 results and expanded Phase 2 SOLSTICE data were presented at AASLD’s Liver Meeting on November 8, 2026.
• Extended SOLSTICE results showed sustained viral suppression, with improved or stable liver stiffness in most patients assessed.
• A separate exploratory analysis found sustained viral suppression following treatment discontinuation in 10 patients, but does not establish a cure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-071908), on November 09, 2026, and is solely responsible for the information contained therein.